The Principal Author

Professor Wei-Ping Liu was born in 1963 in the People's Republic of China and graduated in 1983 from Wuhan University. He obtained his Master's degree in the chemistry of the precious metals in 1986 at the Kunming Institute of Precious Metals, where he is currently a research professor and the Head of the Chemistry and Pharmacy Department. He specialises in research and development on platinum-based antitumour compounds.

  • View the full article text
  • Download this article PDF (826 kb)
  • Download the entire issue PDF
    (3545 kb)
  • View previous summary
  • View next summary

Novel Lipophilic Platinum(II) Compounds of Salicylate Derivatives

Wei-Ping Liu*

Qing-Song Ye

Yao Yu

Xi-Zhu Chen

Shu-Qian Hou

Platinum-Based Drug Lab, Kunming Institute of Precious Metals, Kunming, Yunnan 650021, P.R. China
*

Li-Guang Lou

Yong-Ping Yang

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China

Yi-Ming Wang

Qiang Su

Tsinghua University, Department of Chemistry, Beijing 100084, P.R. China

Platinum Metals Review

Volume 52 Issue 3 July 2008 Pages 163-171
DOI 10.1595/147106708X324845

Article Synopsis

A series of novel lipophilic platinum(II) compounds containing salicylate derivatives as the leaving group have been designed, synthesised and characterised. Most of the platinum compounds exhibit high solubility and have a partition coefficient suited to liposomal encapsulation. Some of the compounds are more pharmacologically active and/or less toxic than carboplatin and oxaliplatin. The liposomal formulation of the most promising compound has been successfully prepared with long stability and high encapsulation rate, showing great potential to be developed as a new tumour-target drug.

top